An Immunogenicity and Safety Evaluation of Two Doses of Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age.

Trial Profile

An Immunogenicity and Safety Evaluation of Two Doses of Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2014

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hib vaccine conjugate; MMR-varicella zoster virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Chickenpox; Haemophilus infections; Measles; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 08 Nov 2012 Pivotal clinical trial data has been published in the Pediatric Infectious Disease Journal, according to a Sanofi Pasteur media release.
    • 01 Nov 2012 Primary endpoint 'Immunological-response-rate' has been met.
    • 01 Nov 2012 Results published in the Pediatric Infectious Disease Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top